Chronic cancer pain is a serious complication of malignancy or its treatment. Currently, no comprehensive, universally accepted cancer pain classification system exists. Clarity in classification of common cancer pain syndromes would improve clinical assessment and management. Moreover, an evidence-based taxonomy would enhance cancer pain research efforts by providing consistent diagnostic criteria, ensuring comparability across clinical trials. As part of a collaborative effort between the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) and the American Pain Society (APS), the ACTTION-APS Pain Taxonomy initiative worked to develop the characteristics of an optimal diagnostic system. After the establishment of these characteristics, a working group consisting of clinicians and clinical and basic scientists with expertise in cancer and cancer-related pain was convened to generate core diagnostic criteria for an illustrative sample of 3 chronic pain syndromes associated with cancer (ie, bone pain and pancreatic cancer pain as models of pain related to a tumor) or its treatment (ie, chemotherapy-induced peripheral neuropathy). A systematic review and synthesis was conducted to provide evidence for the dimensions that comprise this cancer pain taxonomy. Future efforts will subject these diagnostic categories and criteria to systematic empirical evaluation of their feasibility, reliability, and validity and extension to other cancer-related pain syndromes. One significant barrier to better understanding the growing dilemma of chronic cancer pain is the lack of consistent diagnostic criteria that can be used in research and clinical settings. A common taxonomy would provide a foundation for studies of the prevalence, as well as the consequences of these pain syndromes for people with cancer, present evidence for the significance of this problem, support the need for improvements in management, and increase research efforts. 153 This standardized classification system would enhance research efforts by ensuring greater homogeneity in pain conditions across clinical trials and support the development of animal models to replicate these cancer pain conditions. Ultimately, valid and reliable diagnostic criteria would facilitate clinical assessment and management and potentially guide prognostic accuracy. 59, 65 Current systems to classify cancer pain provide general clinical utility. Cancer pain is often organized by its intensity (eg, mild, moderate, or severe), its expected time course (eg, acute vs chronic), its presumed underlying pathophysiology (eg, nociceptive vs neuropathic), its location (eg, head and neck pain), or its putative mechanisms (eg, tumor-related, treatmentrelated, pain unrelated to tumor or treatment). 126 Although these general categories are useful, more specific diagnostic criteria would allow more precise diagnosis with therapeutic implications and would enhance research efforts.
Bone pain, postmastectomy pain, head and neck pain, neuropathic pain (disease-related), and chemotherapy-induced peripheral neuropathy (CIPN) were most frequently referenced. These results were correlated with prevalence data of pain reported according to tumor site, that generally show a higher rates of pain reports in people with pancreatic, lung, genitourinary, breast, and prostate cancers. 20 The expert panel considered these and other pain syndromes aiming to initiate the process of taxonomy development with 3 syndromes before extending to the full range of cancer-related pain syndromes at a later time. The challenge in narrowing the selection to 3 syndromes was to achieve a balance between the most prevalent cancer pain syndromes versus areas that have received the most study and thus have the largest body of evidence. Ultimately guiding the selection was the aim to identify syndromes with clinical or research utility (ie, the painful conditions that are most homogeneous in terms of mechanism or presentation and offer the most relevant targets for further research). related to the tumor) or its treatment (CIPN) were unanimously selected. Head and neck pain was omitted because the source of this pain may be multifactorial (eg, tumor, treatmentrelated, or both) and diverse in relationship to specific anatomic location. Similarly, the working group agreed that disease-related neuropathic pain was too broad. Although postsurgical pain syndromes, including postmastectomy pain, were initially included, this group of pain conditions was omitted from the cancer-related pain taxonomy to avoid overlap with a broader discussion of postsurgical pain syndromes being conducted concurrently by a separate working group classifying neuropathic pain.
Then the cancer pain working group generated a classification for these syndromes on the basis of the AAPT multidimensional framework. This work was conducted during the consensus meeting and later refined through online discussion. To ensure that the references were timely, the entire literature review was updated as of January 2015. The report on these findings was written by several members (J.A.P., M.M., M.B.) and reviewed, edited, and approved by all members of the working group.
Results
On the basis of this qualitative review and after extensive discussion, the diagnostic criteria for 3 representative chronic cancer-related pain syndromes were developed collectively by the working group, including cancer-induced bone pain (CIBP), CIPN, and PCP.
Cancer-Induced Bone Pain
It is estimated that 50 to 95% of all patients who die of cancer have bone involvement. 49, 132 The most common cancers to originate in the bone are osteosarcomas. 84 Cancers that frequently metastasize to bone include prostate, breast, lung, and myeloma. 6, 7, 14, 29, 38, 42, 47, 50, 52, 75, 87, 94, 106, 136 Of those with bone metastases, approximately 85% experience pain, with resultant immobility and reduced quality of life. 54 CIBP is a specific pain state with overlapping but distinct features of acute nociceptive, inflammatory, and neuropathic pain processes. 61 Dimension 1. Core Diagnostic Criteria of CIBP-The AAPT core diagnostic criteria for CIBP are summarized in Table 1 . The history must include a cancer diagnosis and imaging evidence of bone disease consistent with primary or metastatic cancer.
Dimension 2. Common Features of CIBP-
The cardinal feature of CIBP is a mixture of continuous background pain (usually described as annoying, dull, gnawing, aching, and/or nagging) punctuated by evoked or spontaneous pain (often described as electric or shock-like) in 1 or more locations generally consistent with the given known distribution of bone lesions, associated with weight-bearing or movement or can occur spontaneously. 14, 22, 40, 43, 48, 61, 63, 72, 73, 85, 88, 92, 95, 113, 123, 125, 130, 132, 133, 140 Generalized bone pain can occur because of the presence of multiple bone lesions or resultant expansion of bone marrow from bone metastases. 26, 61 The distribution of the pain can be localized, radicular, or both. 73 Typical sites of CIBP include the vertebrae (lower thoracic spine and lumbar regions are most prevalent), pelvis, long bones, and ribs. 26, 48 Bone lesions on the skull can result in headache pain due to calvarial, maxillary, or medullary lesions, as well as cranial nerve palsies such as mental nerve numbness or visual difficulties. 25, 26 Chest wall pain can occur as a result of bone lesions in the ribs. 26 As the disease and tumor mass progress, the background pain increases in intensity and interference 61 and is generally responsive to opioid analgesics, alone or in conjunction with nonsteroidal anti-inflammatory drugs. 10, 22, 63, 71, 79, 112 Conversely, spontaneous pain (without specific eliciting stimuli) and evoked pain (ie, in response to standing, weight-bearing, movement, touch, or other stimuli) associated with CIBP are difficult to treat from the onset because of their intermittent nature, which tends to be very rapid in onset, intense, and of short duration. 10, 22, 63, 71, 79, 112 Terminology commonly used in the clinical setting to describe evoked or spontaneous pain include breakthrough pain, incident pain, or a pain flare; however, definitions for these terms often lack precision and may overlap. For example, breakthrough pain is defined as a transitory flare of pain in the setting of chronic pain managed with opioid drugs, 127 yet the evoked pain seen in CIBP can occur during weight-bearing without current opioid use. The International Association for the Study of Pain Taxonomy, the principal resource for definitions related to chronic pain, does not currently address evoked, breakthrough, incident, flare, or spontaneous pain.
Dimension 3. Common Medical Comorbidities for CIBP-The primary comorbidity
for CIBP is the presence of skeletal-related events. These skeletal complications include pathological fractures of long bones, vertebrae, pelvis, rib, and other sites 11, [24] [25] [26] 28, 49, 51, 154 and in some cases spinal cord compression. 56, 63, 73, 132 Dimension 4. Neurobiological, Psychosocial, and Functional Consequences of CIBP-The consequences of CIBP can be serious because they affect biological, psychological, and functional aspects of the patient's life. 38, 73, 137 Although some pathologic fractures produce limited pain, primary or metastatic bone lesions affecting the femur, pelvis, or spine are likely to cause significant pain during standing or ambulation, resulting in reduced mobility. 63 Reduced quality of life and diminished activities of daily living are associated with CIBP. 41, 44, 48, 49, 91, 118, 132, 134, 160 Functional impairment is strongly associated with evoked or breakthrough pain. 92, 113 Fatigue is frequently reported in patients with metastatic bone disease and resultant pain. 133 Depression is common in people with painful bone metastases and has been reported to be significantly associated with impaired quality of life. 134 Additionally, the meaning of pain as a sign of advancing disease in individuals with CIBP has been shown to be correlated with increased pain intensity. 134 Anxiety in men with advanced prostate cancer is associated with increased pain intensity and number of metastatic bone lesions. 86 These studies reveal that the consequences of CIBP are not unlike those seen in chronic noncancer pain syndromes, including impaired function, mood, and quality of life. 60, 155 that includes elements of acute nociceptive pain, inflammatory pain, and neuropathic pain. 58, 61, 70, 103, 125, 132 Distinctive peripheral modifications to bone and nervous tissues occur as well as neurobiological changes at the level of the spinal cord. 61, 70 Acute nociceptive pain occurs because of localized bone destruction, which leads to loss of structural integrity and a decrease in pH. Cancer cells do not destroy bone directly, but rather they express the receptor activator of nuclear factor κB ligand (RANKL), which binds to its receptor, RANK. Activation of the RANKL/RANK pathway stimulates the production of bone-destroying osteoclasts. 103 Osteoclasts resorb bone by forming a highly acidic environment between the osteoclast and the bone. This stimulates the TRPV1 or ASIC3 channels expressed by a significant population of nociceptors that ultimately leads to the perception of incident pain with movement and weight-bearing activities. 61 Inflammatory pain develops when peripheral nerve endings in bone marrow and bone matrix are sensitized by localized inflammatory mediators stimulated by the cancer cells or their associated stromal cells. Locally released factors include bradykinin, endothelins, interleukin-6, granulocyte-macrophage colony-stimulating factor, nerve growth factor, proteases, and tumor necrosis factor −α. 103 This change is generally associated with steady background pain. 61 Neuropathic pain results from compression, distension, increase in sprouting, or denervation of nerve endings and/or axonal structures caused by expansion of the tumor. These changes lead to spontaneous pain and associated altered sensations. 61 Nociceptive and neuropathic mechanisms work in concert to produce a complex mixture of ongoing acute, inflammatory, and neuropathic processes. These processes lead to a hyperexcitable state within the spinal cord, which itself is associated with amplification and modification of noxious and non-noxious peripheral stimuli. 61, 70, 156 Interventions to protect against CIBP have been developed on the basis of current understanding of the underlying neurobiology. Bisphosphonates bind to bone, interfering with osteoclast function, later resulting in osteoclast apoptosis. 103 Osteoprotegerin or denosumab, therapies that interfere with RANKL binding to RANK deplete activated osteoclasts, reduce signs of bone resorption, and diminish bone cancer pain. 146 This is a rapidly evolving area of research and numerous studies are underway to examine compounds that might block CIBP. 146 Regarding putative psychosocial mechanisms associated with CIBP or other risk factors, little is currently understood and additional research is warranted.
Chemotherapy-Induced Peripheral Neuropathy
CIPN is a serious treatment-induced toxicity that can limit function, impair quality of life, and in some cases, diminish the potential for cure when chemotherapy doses need to be reduced. 9 This condition is increasing in prevalence as greater numbers of neurotoxic agents are introduced and as patients live longer with the consequences of neuropathy. In a recent systematic review of 31 studies with data from 4,179 patients, CIPN prevalence was 68.1% in the first month after chemotherapy, 60.0% at 3 months, and 30.0% at 6 months or later. 141 Dimension 1. Core Diagnostic Criteria of CIPN-CIPN occurs in oncology patients when treatment involves a neurotoxic agent. A temporal relationship exists between the onset of symptoms and the starting, stopping, and duration of therapy. 34, 37, 46, 62, 78, 148 Peripheral sensory and motor nerve damage or dysfunction are the putative mechanisms for CIPN. 36, 37, 62, 101, 121, 148, 151, 162 CIPN poses a significant challenge for the patient and clinician in terms of diagnosis, management, and associated reductions in function and quality of life, particularly in patients with coexisting conditions or disorders that involve the peripheral nervous system (eg, diabetes, HIV). 2, 33, 68, 78, 80, 81, 104, 120, 121, 148, 151 Table 2 shows the core diagnostic criteria for CIPN.
Dimension 2. Common Features of CIPN-
The cardinal feature of dose-limiting CIPN is a gradually progressive distal symmetrical sensory neuropathy (stocking/glove distribution), which may be associated with diminished motor function. However, more often than not motor symptoms are absent until later stages of CIPN. 3, 13, 36, 37, 62, 78, 80, 101, 121, 148, 151, 162 Neuropathy in the feet without involvement in the hands is common. In addition to descriptors such as "tingling" or "burning," patients often describe these sensory abnormalities with terms such as "discomfort" or "unpleasant." Cramping, more common in the lower limbs, may be reported. 151 Clinical examination reveals sensory loss to one or more sensory modalities and/or evoked pain in a stocking and glove distribution. These findings include hypoesthesia (a bilateral increase in detection thresholds to tactile, vibration, or non-noxious warm or cool stimuli), 53, 57, 78 or hypoalgesia (a bilateral increase in pain detection thresholds to blunt pressure or pinprick stimuli), 53, 57, 78 or hyperalgesia (a bilateral decrease in pain detection threshold to noxious heat or cold stimuli). 18, 53 The anatomic distribution of these physical examination findings may not correspond exactly to the sensory symptoms. 2, 30, 46, 53, 78, 80, 109, 115, 120, 148, 152, 158, 162 Signs and symptoms of CIPN, including pain, commonly begin in the lower extremities followed by the upper extremities and progress proximally. 78 However, not all go on to experience neuropathy in the upper extremities. The temporal features of CIPN are rapid onset (hours or days) of sensory abnormalities after initiation of neurotoxic chemotherapy. 78, 101 In most cases, the onset of CIPN symptoms and signs is progressive; beginning with mild paresthesias in the lower extremities, becoming progressively more intense, and advancing proximally with cumulative dose exposure. 78, 101 Some patients may experience a reduction in the intensity of symptoms between treatment cycles-sometimes referred to as a waxing and waning effect. 122 In some cases, symptoms and signs of CIPN may continue or worsen after treatment hasended, a phenomenon known as 'coasting.' 37, 78, 101 Increasing evidence suggests that pre-existing sensory deficits (clinical or subclinical neuropathy) are associated with the onset of more extensive and severe CIPN symptoms and signs. 18, 53 The prevalence of autonomic changes associated with CIPN is poorly understood, but can include serious complications such as falls related to orthostatic hypotension. 1 Agents most likely to result in CIPN include platinum-based drugs (eg, cisplatin, carboplatin, and oxaliplatin), vinca alkaloids (eg, vincristine, vinblastine), taxanes (eg, paclitaxel, docetaxel), bortezomib, thalidomide, lenalidomide, eribulin, and ixabepilone. The frequency and severity of CIPN is generally related to the specific drug, dose, schedule (eg, more prevalent with weekly vs every 3 weeks dosing of paclitaxel), speed of administration, and duration of therapy. 111 In the case of bortezomib, route of delivery affected the prevalence of CIPN. Peripheral neuropathy of any grade was significantly less common with subcutaneous bortezomib administration compared with intravenous delivery. 114 Sensations described by patients vary with the administered chemotherapeutic agent. In a recent prospective study that compared the experience of patients receiving docetaxel versus oxaliplatin, tingling was the most common symptom experienced by both groups, yet pain and discomfort associated with cold was uniquely reported by those who received oxaliplatin. 157 Motor weakness, with a similar peripheral distribution to sensory alterations, can occur in CIPN, but overall is observed less frequently than sensory abnormalities. 62, 101, 141 However, patients frequently show a decrease in mechanosensory function, measured using a timed pegboard test or the time taken to button a shirt. 16, 17, 128 Importantly, impaired proprioception is reported by many patients with CIPN, described as feeling unbalanced, particularly in the absence of visual cues when walking or standing (eg, in dark settings, when closing one's eyes in the shower). 78, 116 Clinical examination may reveal a positive Romberg sign and generalized ataxia in more severe cases. 124 Symmetrical loss of deep tendon reflexes (Achilles or bra-chioradialis) is a sign of more advanced CIPN. 78 Dimension 3. Common Medical Comorbidities of CIPN-People at greatest risk for CIPN are believed to include those with comorbid conditions known to contribute to neuropathy, including diabetes, obesity, and HIV. 81, 128, 141 Pharmacogenetic profiling of genetic polymorphisms has been conducted to identify susceptibility to CIPN on the basis of genetic polymorphisms. For example, polymorphisms in the CYP2C8 and CYP3A5 genes that encode for paclitaxel-metabolizing enzymes were found to be associated with CIPN. 31, 82 Although pharmacogenetic profiling may one day identify patients at greater risk for severe CIPN, the data so far are insufficient to draw any definitive conclusions. Dimension 4. Neurobiological, Psychosocial, and Functional Consequences of CIPN-Terminal axonal degeneration and axonal microtubule disruption are the most common pathophysiologic consequences observed in CIPN. 78 Psychosocial consequences of CIPN include depression, anxiety, impaired sleep, and other mood changes. 69, 83, 151, 157 The functional outcomes of CIPN range from mild symptoms that do not interfere with activities of daily living to moderate and severe dose-limiting sensory and motor alterations that interfere with activities of daily living. 32, [34] [35] [36] [37] 131 The need to limit doses of chemotherapy because of CIPN can lead to shortened survival. In the most severe cases sensory and motor alterations are disabling, resulting in paralysis, complete loss of function, or both. 101 • Disruption of axoplasmic microtubule-mediated transport causing distal axonopathy, a known cellular effect of many chemotherapy agents;
• Distal axonal degeneration;
• Direct damage to sensory nerve cell bodies of the dorsal root ganglia;
• Mitochondrial dysfunction;
• Activation of protein kinases and extracellular kinases (associated with cisplatininduced CIPN);
• Oxaliplatin is associated with actual nerve cell death and decreased epidermal nerve fiber density with each cycle, as well as decreased conduction velocity and amplitude;
• Alteration of gene expression thought to be involved in pain mediation in spinal cord dorsal horn (associated with vincristine exposure);
• Decrease in the density of gray matter after 1 month in women with breast cancer experiencing CIPN;
• Central sensitization as a consequence of long-term peripheral nerve injury.
A recent systematic review explored risk factors for CIPN and reported the following elements: baseline neuropathy, smoking, abnormal creatinine clearance, and distinct sensory changes during chemotherapy treatment, including cold allodynia and cold hyperalgesia. 141 Sensory changes during chemotherapy treatment, including increased pain and neuronal hyperexcitability, are also predictors of CIPN. 141 A prospective study of patients receiving oxaliplatin and followed for 1 year reported that patients with elevated heat detection thresholds (higher temperature levels were needed to perceive heat) before receiving chemotherapy were more likely to experience intense CIPN. 128 Few protective factors for CIPN have been identified. A recent investigation used large Medicare claims data and reported that a history of autoimmune disease was associated with reduced risk of CIPN. 81 Regarding prevention of CIPN, a recent clinical practice guideline from the American Society of Clinical Oncology reviewed existing evidence. After extensive analysis, the authors were unable to recommend any agents to prevent this syndrome because of the lack of high-quality evidence. 80 
Pancreatic Cancer Pain
The estimated incidence of pancreatic cancer for 2016 is more than 53,000 in the United States, with approximately 42,000 dying from this disease. 144 Risk factors for pancreatic cancer include family history, obesity, smoking, and chronic pancreatitis. 89 abdominal pain is a common presenting symptom of pancreatic cancer. The prevalence of pain associated with pancreatic cancer ranges from 72 to 100%. 15 Dimension 1. Core Diagnostic Criteria of PCP-PCP occurs in the presence of a diagnosis of pancreatic cancer confirmed by imaging evidence of an epigastric mass and/or biopsy that establishes the diagnosis. Table 3 shows the core diagnostic criteria.
Dimension 2. Common Features of PCP-
The cardinal features of PCP are upper abdominal pain with frequent extension to the back, either to the low back or the region between the scapulae spreading laterally, and unexplained weight loss. 143 Less frequently PCP is diffuse within the abdomen or referred to the lower abdominal quadrants. 27, 90 The pain is often described as dull, aching, gnawing, or spasmodic 27, 143 and the intensity can fluctuate throughout the day with position (eg, exacerbated by supine positioning) and food ingestion. 143 Pain intensity usually increases with disease severity. However, because this cancer is often diagnosed late, 20 to 30% of patients report moderate to severe pain at diagnosis. 27 The back pain associated with PCP may be worse when the patient is supine and eased by sitting forward. 27, 90, 143 Dimension 3. Common Medical Comorbidities of PCP-Jaundice and dark urine can be a presenting symptom in cancers of the pancreatic head. 143 Unexplained weight loss, anorexia, diabetes, and other sequelae of pancreatic cancer or its treatment are common. 15, 90, 143 To date, few medical comorbidities of PCP have been identified.
Dimension 4. Neurobiological, Psychosocial, and Functional
Consequences of PCP-Because pancreatic cancer is highly associated with pain, it is difficult to discern whether other symptoms are related to the cancer or pain. Several studies have documented a very high prevalence of depressed mood in patients with pancreatic cancer, higher than other cancers with similar prognoses. 8, 27, 45 Symptom burden in general is high in this population, notably including disturbed sleep and fatigue 90 as well as nausea and vomiting associated with obstruction or delayed gastric emptying. 15
Dimension 5. Putative Neurobiological and Psychosocial Mechanisms, Risk
Factors, and Protective Factors for PCP-Pain occurs in 90% of patients with cancer of the head of the pancreas and is much less common in cancer of pancreatic body or tail. 27, 64, 143 Back pain often indicates that retroperitoneal or celiac plexus infiltration has occurred. 143 Putative mechanisms include compression or infiltration (perineural invasion) of splanchnic nerves in the celiac plexus by direct local tu-mor expansion, 8, 19, 117, 143 as well as compression of surrounding tissues and organs. Celiac plexus block has been reported to be effective in relieving PCP. 4, 107, 135 It is unclear if relief signifies extension of tumor into the plexus, or interruption of visceral afferent neurons that are also found in the plexus. No other risk factors or protective factors for PCP could be identified.
syndromes revealed the limitations in our existing nomenclature. Current studies attempting to characterize and establish prevalence rates for specific cancer pain syndromes are hampered by the absence of explicit definitions. A clear example is the large, prospective study by Ventzel and colleagues comparing neuropathy characteristics in patients receiving oxaliplatin versus docetaxel. 157 Although the prevalence of pain in the hands and feet was approximately equal between the 2 groups, on further analysis, a significant percentage of those treated with docetaxel reported less burning and numbness, suggesting the pain was not consistent with CIPN. The investigators postulated this difference may be related to the use of adjuvant endocrine therapies, such as the aromatase inhibitors, often prescribed for those who have received docetaxel. These endocrine therapies are known to cause arthralgias, myalgias, and carpal tunnel syndrome. 110, 142 The investigators used a variety of questionnaires to determine these differences, yet not all clinicians or researchers will be able to use such an extensive battery of measures. It is our hope that the core diagnostic criteria will help future investigators to not only better characterize cancer pain syndromes, as was done in this study, but to differentiate them from related phenomenon to avoid inaccurate interpretations. 100 The consequences of cancer pain can be significant, including deleterious effects on function, mood, sleep, fatigue, and ultimately, quality of life. 60, 155 Additionally, increased intensity of cancer pain is associated with heightened suffering in those at end of life. 159 Finally, studies support the association between pain and reduced survival, demanding more urgent attention to this symptom. 76, 129 More research is warranted to discern the neurobiological, psychological, and functional consequences of each of these and other cancer pain syndromes.
Another area that demands additional study is the determination of the mechanisms of cancer pain. Although important work has begun in the area of CIBP, 39, 102, 103, 105 CIPN, 66, 74, 97, 98 and PCP, 55, 93 additional research is needed to elucidate the neurobiological factors responsible for cancer pain. An exciting line of investigation is the interactions among the cancer microenvironment, the primary afferent nociceptor, and the immune system. 138, 139 An additional area of clarification relates to risk factors and protective determinants for cancer pain. Early research exploring cancer pain focused on clinical or biological factors, such as cancer diagnosis, stage of disease, or treatment. In recent important work, Miaskowski and colleagues reported that cancer patients with the highest symptom burden were significantly younger, more likely to be female and nonwhite, had lower levels of social support, lower socioeconomic status, poorer functional status, and a higher level of comorbidity. 108 In a large study of people with breast cancer, colorectal cancer, or prostate cancer, Lewis et al reported that factors associated with more severe CIPN included colon versus other cancers, the duration and type of therapy, poor socioeconomic status, and black race. 96 Factors influencing cancer pain must be expanded in future studies, including psychosocial factors 60 and overlapping chronic pain conditions and comorbidities. 100 Additionally, identification of genetic polymorphisms might allow for the identification of those at risk for these painful syndromes, as well as direct prevention and treatment innovations.
Finally, an emerging area of research that requires further investigation is the development of phenotypic profiles of cancer pain syndromes on the basis of symptoms and clinical signs. Recent studies in noncancer chronic pain syndromes (such as diabetic peripheral neuropathy) suggest that stratification of patients into homogeneous groups on the basis of symptom profiles may be advantageous for analgesic drug trials and ultimately lead to a more targeted approach to cancer pain management. 67, 150 This proposed taxonomy presents early work in developing a classification system for cancer-related pain conditions. Current classification systems focusing on duration (acute vs chronic) or presumed etiology (related to the cancer, related to treatment, or unrelated) do not provide the specificity needed to clearly define distinct cancer pain syndromes. There were numerous challenges in the development process, notably limitations in existing research related to cancer pain. Studies are often hampered by a wide array of weaknesses, including heterogeneous populations, small sample sizes, dissimilar assessment tools and techniques, and inadequate duration of investigations. Although the working group strove to identify diagnostic criteria that were absolutely necessary to describe each painful syndrome, when these criteria are applied more broadly, controversy will arise and modification will likely be indicated. Future work will now be required to validate this proposed taxonomy in populations of people with cancer and determine the feasibility of its use in clinical as well as research settings. Investigators studying these 3 syndromes should incorporate the core diagnostic criteria when using research methods. Clinicians may find the use of the criteria of benefit when considering the differential diagnosis of complex cancer pain syndromes. This current undertaking classified just 3 syndromes; much additional work is needed to characterize the many other painful syndromes that occur in individuals diagnosed with cancer.
Conclusions
Three cancer pain syndromes, 2 related to cancer, and 1 related to a common cancer treatment, were classified using the AAPT multidimensional chronic pain taxonomy. Future work will show the validity and reliability of these proposed diagnostic criteria. 21 As our understanding of these cancer pain conditions matures, it is expected that the taxonomy will expand and evolve. It is the hope of this working group that classification of these cancer pain syndromes will ultimately strengthen clinical, scientific, and educational efforts around cancer pain. Transforming our understanding of cancer pain is urgently needed to improve its management as well as improve patients' relief and survivors' quality of life. Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram. Preferred Reporting Items for Systematic Reviews and Meta-Analyses is an evidence-based minimum set of items for reporting systematic reviews. 
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Presence of evoked or spontaneous pain (often described as electric or shock-like) in 1 or more locations generally consistent with known distribution of bone lesions, associated with weight-bearing or movement or can occur spontaneously 40, 41, 43, 49, 50, 61, 85, 92, 133 4 Clinical examination over the site of pain reveals:
Hyperalgesia to blunt, non-noxious pressure, or pin-prick stimuli, or
Hypoesthesia to non-noxious thermal stimuli, or
Hypoesthesia to light touch stimuli 140 Paice et al. Page 26 
